APO Research
Talk to an analyst

APO RESEARCH · REPORT

FLT3 Antagonists

Compare research editions
View pricing & licenses

Selected research

Industry Research

FLT3 Antagonists Industry Research Report 2026

27 December 2025131 pages

Choose your research edition.

Industry ResearchFLT3 Antagonists Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal FLT3 Antagonists Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal FLT3 Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FLT3 Antagonists Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal FLT3 Antagonists Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global FLT3 Antagonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for FLT3 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for FLT3 Antagonists is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for FLT3 Antagonists is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of FLT3 Antagonists include Astellas Pharma, Bayer, Cipla, Daiichi Sankyo, Glenmark Pharmaceuticals, Lupin Pharma, Mylan, Natco Pharma and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global FLT3 Antagonists market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

FLT3 Antagonists Market by Company

Astellas Pharma

Bayer

Cipla

Daiichi Sankyo

Glenmark Pharmaceuticals

Lupin Pharma

Mylan

Natco Pharma

Novartis

Pfizer

Takeda Pharmaceuticals

Teva

Zydus

Hunan Kelun Pharmaceutical

Hansoh Pharma

Qilu Pharmaceutical

CSPC Pharmaceutical

FLT3 Antagonists Segment by Type

Gilteritinib

Quizartinib

Midostaurin

Sunitinib

Sorafenib

Other

FLT3 Antagonists Segment by Application

Systemic Mastocytosis

Gastrointestinal Stromal Tumors

Renal Cell Carcinoma

Acute Myeloid Leukemia

Hepatocellular Carcinoma

Other

FLT3 Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FLT3 Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FLT3 Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FLT3 Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of FLT3 Antagonists manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of FLT3 Antagonists by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of FLT3 Antagonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global FLT3 Antagonists Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global FLT3 Antagonists Sales (K Units) of Manufacturers (2021-2026) Table 7. Global FLT3 Antagonists Sales Market Share by Manufacturers (2021-2026) Table 8. Global FLT3 Antagonists Revenue of Manufacturers (2021-2026) Table 9. Global FLT3 Antagonists Revenue Share by Manufacturers (2021-2026) Table 10. Global Market FLT3 Antagonists Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global FLT3 Antagonists Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of FLT3 Antagonists, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of FLT3 Antagonists, Product Type & Application Table 14. Global FLT3 Antagonists Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global FLT3 Antagonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Astellas Pharma Company Information Table 19. Astellas Pharma Business Overview Table 20. Astellas Pharma FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Astellas Pharma FLT3 Antagonists Product Portfolio Table 22. Astellas Pharma Recent Developments Table 23. Bayer Company Information Table 24. Bayer Business Overview Table 25. Bayer FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Bayer FLT3 Antagonists Product Portfolio Table 27. Bayer Recent Developments Table 28. Cipla Company Information Table 29. Cipla Business Overview Table 30. Cipla FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Cipla FLT3 Antagonists Product Portfolio Table 32. Cipla Recent Developments Table 33. Daiichi Sankyo Company Information Table 34. Daiichi Sankyo Business Overview Table 35. Daiichi Sankyo FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Daiichi Sankyo FLT3 Antagonists Product Portfolio Table 37. Daiichi Sankyo Recent Developments Table 38. Glenmark Pharmaceuticals Company Information Table 39. Glenmark Pharmaceuticals Business Overview Table 40. Glenmark Pharmaceuticals FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Glenmark Pharmaceuticals FLT3 Antagonists Product Portfolio Table 42. Glenmark Pharmaceuticals Recent Developments Table 43. Lupin Pharma Company Information Table 44. Lupin Pharma Business Overview Table 45. Lupin Pharma FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Lupin Pharma FLT3 Antagonists Product Portfolio Table 47. Lupin Pharma Recent Developments Table 48. Mylan Company Information Table 49. Mylan Business Overview Table 50. Mylan FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Mylan FLT3 Antagonists Product Portfolio Table 52. Mylan Recent Developments Table 53. Natco Pharma Company Information Table 54. Natco Pharma Business Overview Table 55. Natco Pharma FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Natco Pharma FLT3 Antagonists Product Portfolio Table 57. Natco Pharma Recent Developments Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Novartis FLT3 Antagonists Product Portfolio Table 62. Novartis Recent Developments Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Pfizer FLT3 Antagonists Product Portfolio Table 67. Pfizer Recent Developments Table 68. Takeda Pharmaceuticals Company Information Table 69. Takeda Pharmaceuticals Business Overview Table 70. Takeda Pharmaceuticals FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Takeda Pharmaceuticals FLT3 Antagonists Product Portfolio Table 72. Takeda Pharmaceuticals Recent Developments Table 73. Teva Company Information Table 74. Teva Business Overview Table 75. Teva FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Teva FLT3 Antagonists Product Portfolio Table 77. Teva Recent Developments Table 78. Zydus Company Information Table 79. Zydus Business Overview Table 80. Zydus FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Zydus FLT3 Antagonists Product Portfolio Table 82. Zydus Recent Developments Table 83. Hunan Kelun Pharmaceutical Company Information Table 84. Hunan Kelun Pharmaceutical Business Overview Table 85. Hunan Kelun Pharmaceutical FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Hunan Kelun Pharmaceutical FLT3 Antagonists Product Portfolio Table 87. Hunan Kelun Pharmaceutical Recent Developments Table 88. Hansoh Pharma Company Information Table 89. Hansoh Pharma Business Overview Table 90. Hansoh Pharma FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Hansoh Pharma FLT3 Antagonists Product Portfolio Table 92. Hansoh Pharma Recent Developments Table 93. Qilu Pharmaceutical Company Information Table 94. Qilu Pharmaceutical Business Overview Table 95. Qilu Pharmaceutical FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Qilu Pharmaceutical FLT3 Antagonists Product Portfolio Table 97. Qilu Pharmaceutical Recent Developments Table 98. CSPC Pharmaceutical Company Information Table 99. CSPC Pharmaceutical Business Overview Table 100. CSPC Pharmaceutical FLT3 Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. CSPC Pharmaceutical FLT3 Antagonists Product Portfolio Table 102. CSPC Pharmaceutical Recent Developments Table 103. Global FLT3 Antagonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global FLT3 Antagonists Sales by Region (2021-2026) & (K Units) Table 105. Global FLT3 Antagonists Sales Market Share by Region (2021-2026) Table 106. Global FLT3 Antagonists Sales by Region (2027-2032) & (K Units) Table 107. Global FLT3 Antagonists Sales Market Share by Region (2027-2032) Table 108. Global FLT3 Antagonists Revenue by Region (2021-2026) & (US$ Million) Table 109. Global FLT3 Antagonists Revenue Market Share by Region (2021-2026) Table 110. Global FLT3 Antagonists Revenue by Region (2027-2032) & (US$ Million) Table 111. Global FLT3 Antagonists Revenue Market Share by Region (2027-2032) Table 112. North America FLT3 Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America FLT3 Antagonists Sales by Country (2021-2026) & (K Units) Table 114. North America FLT3 Antagonists Sales by Country (2027-2032) & (K Units) Table 115. North America FLT3 Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 116. North America FLT3 Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe FLT3 Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe FLT3 Antagonists Sales by Country (2021-2026) & (K Units) Table 119. Europe FLT3 Antagonists Sales by Country (2027-2032) & (K Units) Table 120. Europe FLT3 Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe FLT3 Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific FLT3 Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific FLT3 Antagonists Sales by Country (2021-2026) & (K Units) Table 124. Asia Pacific FLT3 Antagonists Sales by Country (2027-2032) & (K Units) Table 125. Asia Pacific FLT3 Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific FLT3 Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 127. South America FLT3 Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America FLT3 Antagonists Sales by Country (2021-2026) & (K Units) Table 129. South America FLT3 Antagonists Sales by Country (2027-2032) & (K Units) Table 130. South America FLT3 Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 131. South America FLT3 Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa FLT3 Antagonists Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa FLT3 Antagonists Sales by Country (2021-2026) & (K Units) Table 134. Middle East and Africa FLT3 Antagonists Sales by Country (2027-2032) & (K Units) Table 135. Middle East and Africa FLT3 Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa FLT3 Antagonists Revenue by Country (2027-2032) & (US$ Million) Table 137. Global FLT3 Antagonists Sales by Type (2021-2026) & (K Units) Table 138. Global FLT3 Antagonists Sales by Type (2027-2032) & (K Units) Table 139. Global FLT3 Antagonists Sales Market Share by Type (2021-2026) Table 140. Global FLT3 Antagonists Sales Market Share by Type (2027-2032) Table 141. Global FLT3 Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 142. Global FLT3 Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 143. Global FLT3 Antagonists Revenue Market Share by Type (2021-2026) Table 144. Global FLT3 Antagonists Revenue Market Share by Type (2027-2032) Table 145. Global FLT3 Antagonists Price by Type (2021-2026) & (US$/Unit) Table 146. Global FLT3 Antagonists Price by Type (2027-2032) & (US$/Unit) Table 147. Global FLT3 Antagonists Sales by Application (2021-2026) & (K Units) Table 148. Global FLT3 Antagonists Sales by Application (2027-2032) & (K Units) Table 149. Global FLT3 Antagonists Sales Market Share by Application (2021-2026) Table 150. Global FLT3 Antagonists Sales Market Share by Application (2027-2032) Table 151. Global FLT3 Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 152. Global FLT3 Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 153. Global FLT3 Antagonists Revenue Market Share by Application (2021-2026) Table 154. Global FLT3 Antagonists Revenue Market Share by Application (2027-2032) Table 155. Global FLT3 Antagonists Price by Application (2021-2026) & (US$/Unit) Table 156. Global FLT3 Antagonists Price by Application (2027-2032) & (US$/Unit) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. FLT3 Antagonists Distributors List Table 160. FLT3 Antagonists Customers List Table 161. FLT3 Antagonists Industry Trends Table 162. FLT3 Antagonists Industry Drivers Table 163. FLT3 Antagonists Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. FLT3 Antagonists Product Image Figure 5. Global FLT3 Antagonists Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global FLT3 Antagonists Market Size (2021-2032) & (US$ Million) Figure 7. Global FLT3 Antagonists Sales (2021-2032) & (K Units) Figure 8. Global FLT3 Antagonists Average Price (US$/Unit) & (2021-2032) Figure 9. Gilteritinib Product Image Figure 10. Quizartinib Product Image Figure 11. Midostaurin Product Image Figure 12. Sunitinib Product Image Figure 13. Sorafenib Product Image Figure 14. Other Product Image Figure 15. Systemic Mastocytosis Product Image Figure 16. Gastrointestinal Stromal Tumors Product Image Figure 17. Renal Cell Carcinoma Product Image Figure 18. Acute Myeloid Leukemia Product Image Figure 19. Hepatocellular Carcinoma Product Image Figure 20. Other Product Image Figure 21. Global FLT3 Antagonists Revenue Share by Manufacturers in 2025 Figure 22. Global Manufacturers of FLT3 Antagonists, Manufacturing Sites & Headquarters Figure 23. Global Top 5 and 10 FLT3 Antagonists Players Market Share by Revenue in 2025 Figure 24. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Global FLT3 Antagonists Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 26. Global FLT3 Antagonists Sales by Region in 2025 Figure 27. Global FLT3 Antagonists Revenue by Region in 2025 Figure 28. North America FLT3 Antagonists Market Size by Country in 2025 Figure 29. North America FLT3 Antagonists Sales Market Share by Country (2021-2032) Figure 30. North America FLT3 Antagonists Revenue Market Share by Country (2021-2032) Figure 31. United States FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Canada FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Mexico FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Europe FLT3 Antagonists Market Size by Country in 2025 Figure 35. Europe FLT3 Antagonists Sales Market Share by Country (2021-2032) Figure 36. Europe FLT3 Antagonists Revenue Market Share by Country (2021-2032) Figure 37. Germany FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. France FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. U.K. FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Italy FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Russia FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Spain FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Netherlands FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Switzerland FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Sweden FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Poland FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Asia Pacific FLT3 Antagonists Market Size by Country in 2025 Figure 48. Asia Pacific FLT3 Antagonists Sales Market Share by Country (2021-2032) Figure 49. Asia Pacific FLT3 Antagonists Revenue Market Share by Country (2021-2032) Figure 50. China FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Japan FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South Korea FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. India FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Australia FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Taiwan FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Southeast Asia FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Southeast Asia FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. South America FLT3 Antagonists Market Size by Country in 2025 Figure 59. South America FLT3 Antagonists Sales Market Share by Country (2021-2032) Figure 60. South America FLT3 Antagonists Revenue Market Share by Country (2021-2032) Figure 61. Brazil FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Argentina FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Chile FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Middle East and Africa FLT3 Antagonists Market Size by Country in 2025 Figure 65. Middle East and Africa FLT3 Antagonists Sales Market Share by Country (2021-2032) Figure 66. Middle East and Africa FLT3 Antagonists Revenue Market Share by Country (2021-2032) Figure 67. Egypt FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. South Africa FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Israel FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Türkiye FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 71. GCC Countries FLT3 Antagonists Revenue Growth Rate (2021-2032) & (US$ Million) Figure 72. Global FLT3 Antagonists Sales Market Share by Type (2021-2032) Figure 73. Global FLT3 Antagonists Revenue Market Share by Type (2021-2032) Figure 74. Global FLT3 Antagonists Price (US$/Unit) by Type (2021-2032) Figure 75. Global FLT3 Antagonists Sales Market Share by Application (2021-2032) Figure 76. Global FLT3 Antagonists Revenue Market Share by Application (2021-2032) Figure 77. Global FLT3 Antagonists Price (US$/Unit) by Application (2021-2032) Figure 78. FLT3 Antagonists Value Chain Figure 79. FLT3 Antagonists Production Mode & Process Figure 80. Direct Comparison with Distribution Share Figure 81. Distributors Profiles Figure 82. FLT3 Antagonists Industry Opportunities and Challenges

Scope & coverage.

Types
  • Gilteritinib
  • Quizartinib
  • Midostaurin
  • Sunitinib
  • Sorafenib
  • Other
Applications
  • Systemic Mastocytosis
  • Gastrointestinal Stromal Tumors
  • Renal Cell Carcinoma
  • Acute Myeloid Leukemia
  • Hepatocellular Carcinoma
  • Other
Companies covered
  • Astellas Pharma
  • Bayer
  • Cipla
  • Daiichi Sankyo
  • Glenmark Pharmaceuticals
  • Lupin Pharma
  • Mylan
  • Natco Pharma
  • Novartis
  • Pfizer
  • Takeda Pharmaceuticals
  • Teva
  • Zydus
  • Hunan Kelun Pharmaceutical
  • Hansoh Pharma
  • Qilu Pharmaceutical
  • CSPC Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global FLT3 Antagonists Market Size (2021-2032)
  4. 2.2.2 Global FLT3 Antagonists Sales (2021-2032)
  5. 2.2.3 Global FLT3 Antagonists Market Average Price (2021-2032)
  6. 2.3 FLT3 Antagonists by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Gilteritinib
  9. 2.3.3 Quizartinib
  10. 2.3.4 Midostaurin
  11. 2.3.5 Sunitinib
  12. 2.3.6 Sorafenib
  13. 2.3.7 Other
  14. 2.4 FLT3 Antagonists by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Systemic Mastocytosis
  17. 2.4.3 Gastrointestinal Stromal Tumors
  18. 2.4.4 Renal Cell Carcinoma
  19. 2.4.5 Acute Myeloid Leukemia
  20. 2.4.6 Hepatocellular Carcinoma
  21. 2.4.7 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global FLT3 Antagonists Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global FLT3 Antagonists Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global FLT3 Antagonists Revenue of Manufacturers (2021-2026)
  4. 3.4 Global FLT3 Antagonists Average Price by Manufacturers (2021-2026)
  5. 3.5 Global FLT3 Antagonists Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of FLT3 Antagonists, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of FLT3 Antagonists, Product Type & Application
  8. 3.8 Global Manufacturers of FLT3 Antagonists, Established Date
  9. 3.9 Global FLT3 Antagonists Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Astellas Pharma
  2. 4.1.1 Astellas Pharma Company Information
  3. 4.1.2 Astellas Pharma Business Overview
  4. 4.1.3 Astellas Pharma FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Astellas Pharma FLT3 Antagonists Product Portfolio
  6. 4.1.5 Astellas Pharma Recent Developments
  7. 4.2 Bayer
  8. 4.2.1 Bayer Company Information
  9. 4.2.2 Bayer Business Overview
  10. 4.2.3 Bayer FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bayer FLT3 Antagonists Product Portfolio
  12. 4.2.5 Bayer Recent Developments
  13. 4.3 Cipla
  14. 4.3.1 Cipla Company Information
  15. 4.3.2 Cipla Business Overview
  16. 4.3.3 Cipla FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Cipla FLT3 Antagonists Product Portfolio
  18. 4.3.5 Cipla Recent Developments
  19. 4.4 Daiichi Sankyo
  20. 4.4.1 Daiichi Sankyo Company Information
  21. 4.4.2 Daiichi Sankyo Business Overview
  22. 4.4.3 Daiichi Sankyo FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Daiichi Sankyo FLT3 Antagonists Product Portfolio
  24. 4.4.5 Daiichi Sankyo Recent Developments
  25. 4.5 Glenmark Pharmaceuticals
  26. 4.5.1 Glenmark Pharmaceuticals Company Information
  27. 4.5.2 Glenmark Pharmaceuticals Business Overview
  28. 4.5.3 Glenmark Pharmaceuticals FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Glenmark Pharmaceuticals FLT3 Antagonists Product Portfolio
  30. 4.5.5 Glenmark Pharmaceuticals Recent Developments
  31. 4.6 Lupin Pharma
  32. 4.6.1 Lupin Pharma Company Information
  33. 4.6.2 Lupin Pharma Business Overview
  34. 4.6.3 Lupin Pharma FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Lupin Pharma FLT3 Antagonists Product Portfolio
  36. 4.6.5 Lupin Pharma Recent Developments
  37. 4.7 Mylan
  38. 4.7.1 Mylan Company Information
  39. 4.7.2 Mylan Business Overview
  40. 4.7.3 Mylan FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Mylan FLT3 Antagonists Product Portfolio
  42. 4.7.5 Mylan Recent Developments
  43. 4.8 Natco Pharma
  44. 4.8.1 Natco Pharma Company Information
  45. 4.8.2 Natco Pharma Business Overview
  46. 4.8.3 Natco Pharma FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Natco Pharma FLT3 Antagonists Product Portfolio
  48. 4.8.5 Natco Pharma Recent Developments
  49. 4.9 Novartis
  50. 4.9.1 Novartis Company Information
  51. 4.9.2 Novartis Business Overview
  52. 4.9.3 Novartis FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Novartis FLT3 Antagonists Product Portfolio
  54. 4.9.5 Novartis Recent Developments
  55. 4.10 Pfizer
  56. 4.10.1 Pfizer Company Information
  57. 4.10.2 Pfizer Business Overview
  58. 4.10.3 Pfizer FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Pfizer FLT3 Antagonists Product Portfolio
  60. 4.10.5 Pfizer Recent Developments
  61. 4.11 Takeda Pharmaceuticals
  62. 4.11.1 Takeda Pharmaceuticals Company Information
  63. 4.11.2 Takeda Pharmaceuticals Business Overview
  64. 4.11.3 Takeda Pharmaceuticals FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Takeda Pharmaceuticals FLT3 Antagonists Product Portfolio
  66. 4.11.5 Takeda Pharmaceuticals Recent Developments
  67. 4.12 Teva
  68. 4.12.1 Teva Company Information
  69. 4.12.2 Teva Business Overview
  70. 4.12.3 Teva FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Teva FLT3 Antagonists Product Portfolio
  72. 4.12.5 Teva Recent Developments
  73. 4.13 Zydus
  74. 4.13.1 Zydus Company Information
  75. 4.13.2 Zydus Business Overview
  76. 4.13.3 Zydus FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Zydus FLT3 Antagonists Product Portfolio
  78. 4.13.5 Zydus Recent Developments
  79. 4.14 Hunan Kelun Pharmaceutical
  80. 4.14.1 Hunan Kelun Pharmaceutical Company Information
  81. 4.14.2 Hunan Kelun Pharmaceutical Business Overview
  82. 4.14.3 Hunan Kelun Pharmaceutical FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Hunan Kelun Pharmaceutical FLT3 Antagonists Product Portfolio
  84. 4.14.5 Hunan Kelun Pharmaceutical Recent Developments
  85. 4.15 Hansoh Pharma
  86. 4.15.1 Hansoh Pharma Company Information
  87. 4.15.2 Hansoh Pharma Business Overview
  88. 4.15.3 Hansoh Pharma FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Hansoh Pharma FLT3 Antagonists Product Portfolio
  90. 4.15.5 Hansoh Pharma Recent Developments
  91. 4.16 Qilu Pharmaceutical
  92. 4.16.1 Qilu Pharmaceutical Company Information
  93. 4.16.2 Qilu Pharmaceutical Business Overview
  94. 4.16.3 Qilu Pharmaceutical FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Qilu Pharmaceutical FLT3 Antagonists Product Portfolio
  96. 4.16.5 Qilu Pharmaceutical Recent Developments
  97. 4.17 CSPC Pharmaceutical
  98. 4.17.1 CSPC Pharmaceutical Company Information
  99. 4.17.2 CSPC Pharmaceutical Business Overview
  100. 4.17.3 CSPC Pharmaceutical FLT3 Antagonists Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 CSPC Pharmaceutical FLT3 Antagonists Product Portfolio
  102. 4.17.5 CSPC Pharmaceutical Recent Developments
5 Global FLT3 Antagonists Market Scenario by Region
  1. 5.1 Global FLT3 Antagonists Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global FLT3 Antagonists Sales by Region: 2021-2032
  3. 5.2.1 Global FLT3 Antagonists Sales by Region: 2021-2026
  4. 5.2.2 Global FLT3 Antagonists Sales by Region: 2027-2032
  5. 5.3 Global FLT3 Antagonists Revenue by Region: 2021-2032
  6. 5.3.1 Global FLT3 Antagonists Revenue by Region: 2021-2026
  7. 5.3.2 Global FLT3 Antagonists Revenue by Region: 2027-2032
  8. 5.4 North America FLT3 Antagonists Market Facts & Figures by Country
  9. 5.4.1 North America FLT3 Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America FLT3 Antagonists Sales by Country (2021-2032)
  11. 5.4.3 North America FLT3 Antagonists Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe FLT3 Antagonists Market Facts & Figures by Country
  16. 5.5.1 Europe FLT3 Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe FLT3 Antagonists Sales by Country (2021-2032)
  18. 5.5.3 Europe FLT3 Antagonists Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific FLT3 Antagonists Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific FLT3 Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific FLT3 Antagonists Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific FLT3 Antagonists Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America FLT3 Antagonists Market Facts & Figures by Country
  41. 5.7.1 South America FLT3 Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America FLT3 Antagonists Sales by Country (2021-2032)
  43. 5.7.3 South America FLT3 Antagonists Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa FLT3 Antagonists Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa FLT3 Antagonists Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa FLT3 Antagonists Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa FLT3 Antagonists Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global FLT3 Antagonists Sales by Type (2021-2032)
  2. 6.1.1 Global FLT3 Antagonists Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global FLT3 Antagonists Sales Market Share by Type (2021-2032)
  4. 6.2 Global FLT3 Antagonists Revenue by Type (2021-2032)
  5. 6.2.1 Global FLT3 Antagonists Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global FLT3 Antagonists Revenue Market Share by Type (2021-2032)
  7. 6.3 Global FLT3 Antagonists Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global FLT3 Antagonists Sales by Application (2021-2032)
  2. 7.1.1 Global FLT3 Antagonists Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global FLT3 Antagonists Sales Market Share by Application (2021-2032)
  4. 7.2 Global FLT3 Antagonists Revenue by Application (2021-2032)
  5. 7.2.1 Global FLT3 Antagonists Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global FLT3 Antagonists Revenue Market Share by Application (2021-2032)
  7. 7.3 Global FLT3 Antagonists Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 FLT3 Antagonists Value Chain Analysis
  2. 8.1.1 FLT3 Antagonists Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 FLT3 Antagonists Production Mode & Process
  5. 8.2 FLT3 Antagonists Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 FLT3 Antagonists Distributors
  8. 8.2.3 FLT3 Antagonists Customers
9 Global FLT3 Antagonists Analyzing Market Dynamics
  1. 9.1 FLT3 Antagonists Industry Trends
  2. 9.2 FLT3 Antagonists Industry Drivers
  3. 9.3 FLT3 Antagonists Industry Opportunities and Challenges
  4. 9.4 FLT3 Antagonists Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst